|
|
Unsubscribe |
|
If you still haven't downloaded Your First Trade Playbook... |
...please take a few seconds and download it right now before your temporary download link expires. |
Most beginners stay stuck on the sidelines for years because nobody shows them the simple steps between "interested in options" and actually placing a trade. |
This playbook fixes that in one evening. |
I eventually plan to charge for it, so do yourself a favor and download it now... |
That way, no matter how much it costs in the future, you'll have a copy on your computer already. |
Make sense? |
FREE: Your First Trade Playbook << Download Now |
Good Trading, |
Bill Poulos |
P.S. Go here to save a copy of Your First Trade Playbook to your computer before I start charging for it. |
|
FEATURED |
Hims & Hers Is Targeting $6.5B by 2030. The Margin Test. |
Hims & Hers has become one of the more consequential consumer health platforms built in the past decade, and the market knows it. The company posted $753.2 million in revenue for the quarter ending June 30, 2026, with 38% growth, bringing trailing twelve-month revenue to about $2.58 billion. That trajectory is hard to dismiss. What deserves closer scrutiny is whether the unit economics support the destination management has publicly staked out. |
The company's long-term targets call for $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. Getting from $2.6 billion to $6.5 billion in four years implies sustained growth north of 25% annually, even accounting for inorganic contributions. Achievable? Possibly. But the path runs directly through a margin problem that management has not yet resolved. |
Gross margin compressed 12 percentage points to 64% in Q2 2026, down from 76% in the prior-year period. That compression, alongside rising development expenses, produced an $86.3 million net loss compared to a $42.5 million net profit in the same quarter last year. The company frames this as deliberate reinvestment. That framing is defensible, but investors should note that management has indicated gross margins could compress further in the near term as the company prioritizes scaling weight loss, labs, and international markets, which carry a lower margin profile. |
The strategic context matters here. For much of 2024 and into 2025, Hims’ U.S. weight loss growth was heavily influenced by compounded GLP-1 offerings during a period of constrained availability for branded semaglutide. That model has since shifted. Novo Nordisk and Hims reached an agreement announced March 9, 2026, ending a dispute tied to compounded semaglutide. Under the agreement, Hims offers access to Novo’s FDA-approved Ozempic and Wegovy at the same self-pay prices as other telehealth platforms. The compounding premium is off the table. The new relationship can help with product access and reliability, but the pricing power the company once extracted from compounded versions is gone. |
The international push is where the real bet is being placed. Hims agreed to acquire Australian digital health firm Eucalyptus in a transaction valued at up to $1.15 billion, and completed that acquisition on June 2, 2026. Hims said Eucalyptus had an annual revenue run rate north of $450 million and delivered triple-digit year-over-year ARR growth in each quarter of calendar year 2025. Building on earlier acquisitions of ZAVA and Livewell, Hims now holds a leading presence across the U.S., UK, Australian, and Canadian markets, with a growing presence in France, Germany, Ireland, Spain, and Japan. |
That geographic reach is the second-order story the market has not fully priced. Monthly revenue per average subscriber climbed 21% year-over-year to $92 in Q2 2026, suggesting that the platform is deepening its hold on existing customers even as subscriber counts grow. If that dynamic holds internationally, the unit economics of the acquisition improve materially over time. If it doesn't, the company will have spent over a billion dollars building a global brand that generates lower returns than the core U.S. business. |
The risks are not hypothetical. Adjusted EBITDA fell 27% to $60.3 million in Q2 2026, and the company recorded negative operating cash flow of $35.9 million for the quarter, underscoring just how capital-intensive this growth phase has become. Insiders sold $5.5 million worth of shares over the past three months, which is not a disqualifying signal but worth monitoring alongside the cash burn. Regulatory friction remains an ongoing variable. The FDA's posture toward direct-to-consumer telehealth is shifting, and any tightening of prescribing standards could add friction to Hims' async-only, no-lab-required model. |
The bull case rests on one credible premise: Hims & Hers has built a consumer brand with meaningful mindshare in telehealth, and brand equity in healthcare compounds slowly. Reaching nearly 2.9 million subscribers while pivoting away from its highest-margin product line is not a trivial execution feat. The question for investors is whether management can rebuild gross margin toward the 70% range while simultaneously absorbing four international acquisitions and reorienting a weight loss business that was, until recently, built on a model regulators have now constrained. The $6.5 billion target is not fantasy. But the operating leverage required to make the EBITDA side of that equation work remains unproven at this scale. |
-TCI Editorial Team |
|
|
|
IMPORTANT NOTICE AND DISCLAIMER
Investing Media Solutions, LLC ("IMS"), the owner of this website (the "Website"), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the "Publications"). The author or authors of those Publications are solely responsible for their contents. IMS has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications. IMS will NOT be liable for any loss or damage caused by a reader's reliance on information posted on the Website or contained in the Publications. |
|
|
|
|
FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.
This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company's financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications. |
|
|
SUBSTANTIAL RISK IN INVESTMENT.
Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution. Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional. |
|
|
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER
Neither IMS nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization. |
|
|
|
|
At The Cheap Investor, it's our mission to create and provide a community that helps you invest and understand stocks. When TheCheapInvestor was established, we wanted to make the community an inclusive place where investors can come to get ahead! Not just help them with daily stock picks. The Cheap Investor are provided to you for information only and should not be considered as a stock or investment advisor. The Cheap Investor may make available certain information related to trading strategies and stock prices for educational and information purposes only; any information made available should not be construed as an endorsement, recommendation, or sponsorship of any company or security. By visiting this site or using the training materials, you acknowledge and agree that any reliance upon the content or data available through The Cheap Investor is at your own sole risk. You are strongly advised to use your own judgment, research, and consult a professional advisor. |
|
|
Over the years, and with thousands of followers that use our stock picks daily, we promise to always aim to get better at what we do every single day! In addition, our primary focus is on our communication with you. It's really important to us that every time you come to us, you end up leaving with the help you came for to take your investment portfolio to new levels. |
|
|
We particularly appreciate when our following provides feedback via testimonials, reviews, and comments left on our site or social media accounts. Because with that feedback, we can use it to make your next visit to our site even better than the last! |
|
|
Since we put so much effort into the relationship with you, we hope that any investment in us is exactly the way you hoped it would be. Because by choosing to go with https://TheCheapInvestor.com/, it's our promise that we provide a community you will come back to over and over again. |
Now, as much as we care about making investors more successful, we also care about your privacy. TheCheapInvestor is owned and operated by TheCheapInvestor website. |
We're committed to the right to your privacy and strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website. |
What Information Do We Collect? |
When you visit our Web site you may provide us with two types of information: personal information you knowingly choose to disclose that is collected on an individual basis and Web site use information collected on an aggregate basis as you and others browse our Web site. |
|
|
For example, you may need to provide the following information: • Name • Website URL information • Email address • Home and business phone number |
In addition to providing the foregoing information, if you choose to correspond further with us through email, we may retain the content of your email messages together with your email address and our responses. We provide the same protections for these electronic communications that we employ in the maintenance of information received by mail and telephone. It also explains important information that ensures we won't abuse the information that you provide to us in good faith. By accessing and using our website, you can trust that what you want to be kept private, will be kept private. If at any time, you would like to read our Privacy Policy and get a better understanding of your rights and liabilities under the law. |
Feel free to visit our site, find the privacy policy in the footer and read it. If there is something you are concerned about or wish to get more clarity on, please let us know by contacting us at support@thecheapinvestor.com. The Privacy Policy also informs you of how to notify us to stop using your personal information. If you wish to view our official policies, please visit our website https://TheCheapInvestor.com/ |
At The Cheap Investor, we are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website. The Cheap Investor operates the Website. |
Our Privacy Policy, along with our Term & Conditions, governs your use of this site. By using https://TheCheapInvestor/, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy. If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by emailing us at support@thecheapinvestor.com. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the "unsubscribe" link located on the bottom of any marketing email. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example). If you have any questions, simply reply to this email or visit our website to view our official policies. |
|
|
Update your email preferences or unsubscribe here © 2026 The Cheap Investor 203 N La Salle Suite 2100
Chicago , Illinois 60601, United States |
|
|
|
|
|
|
|
|
|
Tidak ada komentar:
Posting Komentar